Colin S. Cooper
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Colin S. Cooper has a total of 162 co-authors. Here are the top co-authors by number of shared publications:
Jeremy Clark
Norwich Medical School, University of East Anglia, Norwich, UK
6 shared publicationsCyril Fisher
Royal Marsden NHS Foundation Trust, London and Sutton, UK
4 shared publicationsJ Clark
Institute of Cancer Research, Male Urological Cancer Research Centre, Sutton, Surrey, UK
4 shared publicationsP Flohr
Institute of Cancer Research, Male Urological Cancer Research Centre, Sutton, UK
4 shared publicationsSandra Edwards
Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK
4 shared publicationsAlan Thompson
Royal Marsden NHS Foundation Trust, London and Sutton, UK
3 shared publications
Latest Publications
- Top Cited PapersOpen Access
- 2 March 2015
- Published by Springer Nature in Nature Genetics
- Vol. 47 (4) , 367-372
Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue
Colin Cooper and colleagues report genome-wide sequences of multiple samples of multifocal cancer and morphologically normal tissue from the prostates of three men. They found high levels of mutations in morphologically normal tissue distant from the cancer, consistent with field effects. Genome-wide DNA sequencing was used to decrypt the phylogeny of multiple samples from distinct areas of cancer and morphologically normal tissue taken from the prostates of three men. Mutations were present at high levels in morphologically normal tissue distant from the cancer, reflecting clonal expansions, and the underlying mutational processes at work in morphologically normal tissue were also at work in cancer. Our observations demonstrate the existence of ongoing abnormal mutational processes, consistent with field effects, underlying carcinogenesis. This mechanism gives rise to extensive branching evolution and cancer clone mixing, as exemplified by the coexistence of multiple cancer lineages harboring distinct ERG fusions within a single cancer nodule. Subsets of mutations were shared either by morphologically normal and malignant tissues or between different ERG lineages, indicating earlier or separate clonal cell expansions. Our observations inform on the origin of multifocal disease and have implications for prostate cancer therapy in individual cases.
- 2 March 2015
- Published by Springer Nature in Nature Genetics
- Vol. 47 (4) , 367-372
Top Cited PapersOpen AccessAnalysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue
Colin Cooper and colleagues report genome-wide sequences of multiple samples of multifocal cancer and morphologically normal tissue from the prostates of three men. They found high levels of mutations in morphologically normal tissue distant from the cancer, consistent with field effects. Genome-wide DNA sequencing was used to decrypt the phylogeny of multiple samples from distinct areas of cancer and morphologically normal tissue taken from the prostates of three men. Mutations were present at high levels in morphologically normal tissue distant from the cancer, reflecting clonal expansions, and the underlying mutational processes at work in morphologically normal tissue were also at work in cancer. Our observations demonstrate the existence of ongoing abnormal mutational processes, consistent with field effects, underlying carcinogenesis. This mechanism gives rise to extensive branching evolution and cancer clone mixing, as exemplified by the coexistence of multiple cancer lineages harboring distinct ERG fusions within a single cancer nodule. Subsets of mutations were shared either by morphologically normal and malignant tissues or between different ERG lineages, indicating earlier or separate clonal cell expansions. Our observations inform on the origin of multifocal disease and have implications for prostate cancer therapy in individual cases.
- 1 May 2012
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 103, S48
PD-0123 ANDROGEN RECEPTOR FISH ASSAY PREDICTS POOR SURVIVAL IN EARLY HUMAN PROSTATE CANCER
- 1 May 2012
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 103, S48
PD-0123 ANDROGEN RECEPTOR FISH ASSAY PREDICTS POOR SURVIVAL IN EARLY HUMAN PROSTATE CANCER
- Open Access
- 15 November 2010
- Published by BMJ in Journal of Clinical Pathology
- Vol. 64 (1) , 88-90
High-density tissue microarrays from prostate needle biopsies
Background Formalin-fixed prostate biopsies are frequently the only tissue collected at the time of prostate cancer diagnosis. There is therefore a requirement for techniques that allow the use of these prostate biopsy specimens in a high-throughput analysis of immunohistochemical and fluorescence-in-situ-hybridisation-detected biomarkers. Methods The authors have previously described methods that allow tissue microarray (TMA) construction from prostate biopsies. Here, we describe significant technical innovations that provide an easier and more robust system of biopsy–TMA construction. Results and discussion The TMAs produced are of a high density (up to 104 cores each, 8×13) and allow a multiplex analysis of biomarkers in the context of clinical trials.
- 15 November 2010
- Published by BMJ in Journal of Clinical Pathology
- Vol. 64 (1) , 88-90
Open AccessHigh-density tissue microarrays from prostate needle biopsies
Background Formalin-fixed prostate biopsies are frequently the only tissue collected at the time of prostate cancer diagnosis. There is therefore a requirement for techniques that allow the use of these prostate biopsy specimens in a high-throughput analysis of immunohistochemical and fluorescence-in-situ-hybridisation-detected biomarkers. Methods The authors have previously described methods that allow tissue microarray (TMA) construction from prostate biopsies. Here, we describe significant technical innovations that provide an easier and more robust system of biopsy–TMA construction. Results and discussion The TMAs produced are of a high density (up to 104 cores each, 8×13) and allow a multiplex analysis of biomarkers in the context of clinical trials.
- Open Access
- 28 July 2009
- Published by BMJ in Journal of Clinical Pathology
- Vol. 62 (8) , 694-698
An improved method for constructing tissue microarrays from prostate needle biopsy specimens
Background: Prostate cancer diagnosis is routinely made by the histopathological examination of formalin fixed needle biopsy specimens. Frequently this is the only cancer tissue available from the patient for the analysis of diagnostic and prognostic biomarkers. There is, therefore, an urgent need for methods that allow the high-throughput analysis of these biopsy samples using immunohistochemical (IHC) markers and fluorescence in situ hybridisation (FISH) analysis based markers.Methods: A method that allows the construction of tissue microarrays (TMAs) from diagnostic prostate needle biopsy cores has previously been reported. However, the technique only allows the production of low-density biopsy TMAs with a maximum of 20 cores per TMA. Here two methods are presented that allow the rapid and uniform production of biopsy TMAs containing between 54 and 72 biopsy cores. IHC and FISH techniques were used to detect biomarker status.Results: Biopsy TMAs were constructed from prostate needle biopsy specimens taken from 102 patients entered into an active surveillance trial and 201 patients in a radiotherapy trial. The detection rate for cancer in slices of these biopsy TMAs was 66% and 79% respectively. Slices of a biopsy TMA prepared from biopsies from active surveillance patients were used to detect multiple IHC markers and to scoreTMPRSS2-ERGfusion status in a FISH-based assay.Conclusions: The construction of biopsy TMAs provides an effective method for the multiplex analysis of IHC and FISH markers and for their assessment as prognostic biomarkers in the context of clinical trials.
- 28 July 2009
- Published by BMJ in Journal of Clinical Pathology
- Vol. 62 (8) , 694-698
Open AccessAn improved method for constructing tissue microarrays from prostate needle biopsy specimens
Background: Prostate cancer diagnosis is routinely made by the histopathological examination of formalin fixed needle biopsy specimens. Frequently this is the only cancer tissue available from the patient for the analysis of diagnostic and prognostic biomarkers. There is, therefore, an urgent need for methods that allow the high-throughput analysis of these biopsy samples using immunohistochemical (IHC) markers and fluorescence in situ hybridisation (FISH) analysis based markers.Methods: A method that allows the construction of tissue microarrays (TMAs) from diagnostic prostate needle biopsy cores has previously been reported. However, the technique only allows the production of low-density biopsy TMAs with a maximum of 20 cores per TMA. Here two methods are presented that allow the rapid and uniform production of biopsy TMAs containing between 54 and 72 biopsy cores. IHC and FISH techniques were used to detect biomarker status.Results: Biopsy TMAs were constructed from prostate needle biopsy specimens taken from 102 patients entered into an active surveillance trial and 201 patients in a radiotherapy trial. The detection rate for cancer in slices of these biopsy TMAs was 66% and 79% respectively. Slices of a biopsy TMA prepared from biopsies from active surveillance patients were used to detect multiple IHC markers and to scoreTMPRSS2-ERGfusion status in a FISH-based assay.Conclusions: The construction of biopsy TMAs provides an effective method for the multiplex analysis of IHC and FISH markers and for their assessment as prognostic biomarkers in the context of clinical trials.
- Open Access
- 7 April 2009
- Published by Wiley in BJU International
- Vol. 103 (9) , 1256-1269
Integration of ERG gene mapping and gene‐expression profiling identifies distinct categories of human prostate cancer
OBJECTIVE: To integrate the mapping of ERG alterations with the collection of expression microarray (EMA) data, as previous EMA analyses have failed to consider the genetic heterogeneity and complex patterns of ERG alteration frequently found in cancerous prostates. MATERIALS AND METHODS: We determined genome‐wide expression levels with GeneChip Human Exon 1.0 ST arrays (Affymetrix, Santa Clara, CA, USA) using RNA prepared from 35 specimens of prostate cancer from 28 prostates. RESULTS: The expression profiles showed clustering, in unsupervised hierarchical analyses, into two distinct prostate cancer categories, with one group strongly associated with indicators of poor clinical outcome. The two categories are not tightly linked to ERG status. By analysis of the data we identified a subgroup of cancers lacking ERG rearrangements that showed an outlier pattern of SPINK1 mRNA expression. There was a major distinction between ERG rearranged and non‐rearranged cancers that involves the levels of expression of genes linked to exposure to β‐oestradiol, and to retinoic acid. CONCLUSIONS: Expression profiling of prostate cancer samples containing single patterns of ERG alterations can provide novel insights into the mechanism of prostate cancer development, and support the view that factors other than ERG status are the major determinants of poor clinical outcome.
- 7 April 2009
- Published by Wiley in BJU International
- Vol. 103 (9) , 1256-1269
Open AccessIntegration of ERG gene mapping and gene‐expression profiling identifies distinct categories of human prostate cancer
OBJECTIVE: To integrate the mapping of ERG alterations with the collection of expression microarray (EMA) data, as previous EMA analyses have failed to consider the genetic heterogeneity and complex patterns of ERG alteration frequently found in cancerous prostates. MATERIALS AND METHODS: We determined genome‐wide expression levels with GeneChip Human Exon 1.0 ST arrays (Affymetrix, Santa Clara, CA, USA) using RNA prepared from 35 specimens of prostate cancer from 28 prostates. RESULTS: The expression profiles showed clustering, in unsupervised hierarchical analyses, into two distinct prostate cancer categories, with one group strongly associated with indicators of poor clinical outcome. The two categories are not tightly linked to ERG status. By analysis of the data we identified a subgroup of cancers lacking ERG rearrangements that showed an outlier pattern of SPINK1 mRNA expression. There was a major distinction between ERG rearranged and non‐rearranged cancers that involves the levels of expression of genes linked to exposure to β‐oestradiol, and to retinoic acid. CONCLUSIONS: Expression profiling of prostate cancer samples containing single patterns of ERG alterations can provide novel insights into the mechanism of prostate cancer development, and support the view that factors other than ERG status are the major determinants of poor clinical outcome.
- Open Access
- 11 November 2008
- Published by Springer Nature in British Journal of Cancer
- Vol. 100 (2) , 240-245
Concepts of epigenetics in prostate cancer development
Substantial evidence now supports the view that epigenetic changes have a role in the development of human prostate cancer. Analyses of the patterns of epigenetic alteration are providing important insights into the origin of this disease and have identified specific alterations that may serve as useful diagnostic and prognostic biomarkers. Examination of cancer methylation patterns supports a stem cell origin of prostate cancer. It is well established that methylation of GSTpi is a marker of prostate cancer, and global patterns of histone marking appear to be linked to cancer prognosis with levels of acetylated histones H3K9, H3K18, and H4K12, and of dimethylated H4R3 and H3K4, dividing low-grade prostate cancer (Gleason 6 or less) into two prognostically separate groups. Elevated levels of several components of the polycomb group protein complex, EZH2, BMI1, and RING1, can also act as biomarkers of poor clinical outcome. Many components of the epigenetic machinery, including histone deacetylase (whose expression level is linked to the TMPRSS2:ERG translocation) and the histone methylase EZH2, are potential therapeutic targets. The recent discovery of the role of small RNAs in governing the epigenetic status of individual genes offers exciting new possibilities in therapeutics and chemoprevention.
- 11 November 2008
- Published by Springer Nature in British Journal of Cancer
- Vol. 100 (2) , 240-245
Open AccessConcepts of epigenetics in prostate cancer development
Substantial evidence now supports the view that epigenetic changes have a role in the development of human prostate cancer. Analyses of the patterns of epigenetic alteration are providing important insights into the origin of this disease and have identified specific alterations that may serve as useful diagnostic and prognostic biomarkers. Examination of cancer methylation patterns supports a stem cell origin of prostate cancer. It is well established that methylation of GSTpi is a marker of prostate cancer, and global patterns of histone marking appear to be linked to cancer prognosis with levels of acetylated histones H3K9, H3K18, and H4K12, and of dimethylated H4R3 and H3K4, dividing low-grade prostate cancer (Gleason 6 or less) into two prognostically separate groups. Elevated levels of several components of the polycomb group protein complex, EZH2, BMI1, and RING1, can also act as biomarkers of poor clinical outcome. Many components of the epigenetic machinery, including histone deacetylase (whose expression level is linked to the TMPRSS2:ERG translocation) and the histone methylase EZH2, are potential therapeutic targets. The recent discovery of the role of small RNAs in governing the epigenetic status of individual genes offers exciting new possibilities in therapeutics and chemoprevention.
- 1 January 2008
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 10 (1) , 50-57
Detection of TMPRSS2-ERG Translocations in Human Prostate Cancer by Expression Profiling Using GeneChip Human Exon 1.0 ST Arrays
- 1 January 2008
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 10 (1) , 50-57
Detection of TMPRSS2-ERG Translocations in Human Prostate Cancer by Expression Profiling Using GeneChip Human Exon 1.0 ST Arrays
- 1 December 2007
- Published by Springer Nature in Nature Reviews Endocrinology
- Vol. 4 (12) , 677-687
Mechanisms of Disease: biomarkers and molecular targets from microarray gene expression studies in prostate cancer
Molecular biomarkers can serve as useful diagnostic markers, as prognostic markers for predicting clinical behavior, or as targets for new therapeutic strategies. Application of expression microarray technology, which allows the expression of all or most of the genes in the human genome to be analyzed simultaneously, has dramatically enhanced the discovery of prostate cancer biomarkers. The diagnostic markers identified include AMACR (α-methylacyl CoA racemase), a protein that has already been translated into clinical use as an aid in distinguishing prostate cancer from benign disease. Individual genes, such as the polycomb gene EZH2 whose expression indicates poor survival, have been identified. The power of microarray technology is that it has allowed the identification of gene signatures (each composed of multiple genes) that might provide improved prediction of clinical outcomes in human prostate cancer. The development of a new method for analyzing expression microarray data, called COPA, has led to the discovery of TMPRSS2–ERG gene fusion involvement in the development of prostate cancer, while expression analysis of castration-resistant prostate cancer has suggested the use of novel therapeutic approaches for advanced disease. Despite these successes, there are limitations in the application of microarray technology to prostate cancer; for example, unlike with other cancers, this approach has failed to provide a consistent unsupervised classification of the disease. Overcoming the reasons for these failures represents a major challenge for future research endeavors.
- 1 December 2007
- Published by Springer Nature in Nature Reviews Endocrinology
- Vol. 4 (12) , 677-687
Mechanisms of Disease: biomarkers and molecular targets from microarray gene expression studies in prostate cancer
Molecular biomarkers can serve as useful diagnostic markers, as prognostic markers for predicting clinical behavior, or as targets for new therapeutic strategies. Application of expression microarray technology, which allows the expression of all or most of the genes in the human genome to be analyzed simultaneously, has dramatically enhanced the discovery of prostate cancer biomarkers. The diagnostic markers identified include AMACR (α-methylacyl CoA racemase), a protein that has already been translated into clinical use as an aid in distinguishing prostate cancer from benign disease. Individual genes, such as the polycomb gene EZH2 whose expression indicates poor survival, have been identified. The power of microarray technology is that it has allowed the identification of gene signatures (each composed of multiple genes) that might provide improved prediction of clinical outcomes in human prostate cancer. The development of a new method for analyzing expression microarray data, called COPA, has led to the discovery of TMPRSS2–ERG gene fusion involvement in the development of prostate cancer, while expression analysis of castration-resistant prostate cancer has suggested the use of novel therapeutic approaches for advanced disease. Despite these successes, there are limitations in the application of microarray technology to prostate cancer; for example, unlike with other cancers, this approach has failed to provide a consistent unsupervised classification of the disease. Overcoming the reasons for these failures represents a major challenge for future research endeavors.
- Top Cited Papers
- 16 July 2007
- Published by Springer Nature in Oncogene
- Vol. 27 (3) , 253-263
Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer
New predictive markers for managing prostate cancer are urgently required because of the highly variable natural history of this disease. At the time of diagnosis, Gleason score provides the gold standard for assessing the aggressiveness of prostate cancer. However, the recent discovery of TMPRSS2 fusions to the ERG gene in prostate cancer raises the possibility of using alterations at the ERG locus as additional mechanism-based prognostic indicators. Fluorescence in situ hybridization (FISH) assays were used to assess ERG gene status in a cohort of 445 prostate cancers from patients who had been conservatively managed. The FISH assays detected separation of 5′ (labelled green) and 3′ (labelled red) ERG sequences, which is a consequence of the TMPRSS2–ERG fusion, and additionally identify interstitial deletion of genomic sequences between the tandemly located TMPRSS2 and ERG gene sequences on chromosome 21. Cancers lacking ERG alterations exhibited favourable cause-specific survival (90% survival at 8 years). We identify a novel category of prostate cancers, characterized by duplication of the fusion of TMPRSS2 to ERG sequences together with interstitial deletion of sequences 5′ to ERG (called ‘2+Edel’), which by comparison exhibited extremely poor cause-specific survival (hazard ratio=6.10, 95% confidence ratio=3.33–11.15, PP=0.003) in addition to that provided by Gleason score and prostate-specific antigen level at diagnosis. Other individual categories of ERG alteration were associated with intermediate or good prognosis. We conclude that determination of ERG gene status, including duplication of the fusion of TMPRSS2 to ERG sequences in 2+Edel, allows stratification of prostate cancer into distinct survival categories.
- 16 July 2007
- Published by Springer Nature in Oncogene
- Vol. 27 (3) , 253-263
Top Cited PapersDuplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer
New predictive markers for managing prostate cancer are urgently required because of the highly variable natural history of this disease. At the time of diagnosis, Gleason score provides the gold standard for assessing the aggressiveness of prostate cancer. However, the recent discovery of TMPRSS2 fusions to the ERG gene in prostate cancer raises the possibility of using alterations at the ERG locus as additional mechanism-based prognostic indicators. Fluorescence in situ hybridization (FISH) assays were used to assess ERG gene status in a cohort of 445 prostate cancers from patients who had been conservatively managed. The FISH assays detected separation of 5′ (labelled green) and 3′ (labelled red) ERG sequences, which is a consequence of the TMPRSS2–ERG fusion, and additionally identify interstitial deletion of genomic sequences between the tandemly located TMPRSS2 and ERG gene sequences on chromosome 21. Cancers lacking ERG alterations exhibited favourable cause-specific survival (90% survival at 8 years). We identify a novel category of prostate cancers, characterized by duplication of the fusion of TMPRSS2 to ERG sequences together with interstitial deletion of sequences 5′ to ERG (called ‘2+Edel’), which by comparison exhibited extremely poor cause-specific survival (hazard ratio=6.10, 95% confidence ratio=3.33–11.15, PP=0.003) in addition to that provided by Gleason score and prostate-specific antigen level at diagnosis. Other individual categories of ERG alteration were associated with intermediate or good prognosis. We conclude that determination of ERG gene status, including duplication of the fusion of TMPRSS2 to ERG sequences in 2+Edel, allows stratification of prostate cancer into distinct survival categories.
- 1 November 2006
- Published by Elsevier in Lung Cancer
- Vol. 54 (2) , 155-162
Nuclear overexpression of the E2F3 transcription factor in human lung cancer
- 1 November 2006
- Published by Elsevier in Lung Cancer
- Vol. 54 (2) , 155-162
Nuclear overexpression of the E2F3 transcription factor in human lung cancer